<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="772">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394416</url>
  </required_header>
  <id_info>
    <org_study_id>2038GCCC</org_study_id>
    <nct_id>NCT04394416</nct_id>
  </id_info>
  <brief_title>Trial of Imatinib for Hospitalized Adults With COVID-19</brief_title>
  <official_title>Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy
      of Imatinib for Hospitalized Adults with COVID-19
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by the severe acute
      respiratory syndrome coronavirus 2 (SARS-CoV-2), and at present with no approved or proven
      antiviral treatment.

      Imatinib is a tyrosine kinase inhibitor that has been approved for treatment of many
      hematologic and solid neoplasm. Imatinib is a weak base that compared to the extracellular
      compartment is enriched over 1000-fold in the lysosome within several hours as a result of
      its lysosomotropic property. Imatinib as a weak base accumulates in lysosomes resulting in
      some antiviral activities by lysosomal alkalization required for virus/cell fusion.

      Imatinib demonstrates in vitro activity against SARS-CoV viruses. Imatinib inhibit SARS-CoV
      and MERS-CoV with micromolar EC50s (range, 9.8 to 17.6 μM) with low toxicity. The mechanism
      of action studies suggested that ABL-1 tyrosine kinase regulates budding or release of
      poxviruses and Ebola virus, demonstrating that the c-ABL-1 kinase signaling pathways play an
      important role in the egress of these viruses. It is also reported that kinase signaling may
      also be important for replication of two members of the Coronaviridae family, SARS-CoV and
      MERS-CoV. In vivo studies performed in the mouse model of vaccinia virus infection showed
      that imatinib was effective in blocking dissemination of the virus.

      Imatinib has anti-inflammatory activity including its effectiveness in a &quot;two-hit&quot; murine
      model of acute lung injury (ALI) caused by combined lipopolysaccharide (LPS) and
      ventilator-induced lung injury (VILI). Imatinib significantly decreased bronchoalveolar
      lavage protein, total cells, neutrophils, and TNFα levels in mice exposed to LPS plus VILI,
      indicating that it attenuates ALI in this clinically relevant model. In another experiment,
      imatinib attenuated ALI when given 4 hours after LPS, suggesting potential efficacy when
      given after the onset of injury. Overall, these results strongly suggest the therapeutic
      potential of imatinib against inflammatory vascular leak and a potential role of imatinib
      combination therapy for patients with acute respiratory distress syndrome (ARDS) on
      mechanical ventilation.

      The investigators hypothesize that addition of imatinib to the best conventional care (BCC)
      improves the outcome of hospitalized adult patients with COVID-19. This hypothesis is on the
      bases of 1) intralysosomal entrapment of imatinib will increase endosomal pH and effectively
      decrease SARS-CoV-2/cell fusion, 2) kinase inhibitory activity of imatinib will interfere
      with budding/release or replication of SARS-CoV-2, and 3) because of the critical role of
      mechanical ventilation in the care of patients with ARDS, imatinib will have a significant
      clinical impact for patients with severe COVID-19 infection in Intensive Care Unit (ICU).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm A: Imatinib
Arm B: Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients with a two-point change using the 8-category ordinal scale</measure>
    <time_frame>Day 14 from baseline</time_frame>
    <description>The ordinal scale is an evaluation of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-Cause mortality</measure>
    <time_frame>Day 28 and Day 60 post baseline</time_frame>
    <description>All-cause mortality post baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to a 2-point clinical change</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>Time to a 2-point clinical change difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>Duration of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ECMO or invasive mechanical ventilation</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>For subjects who are on ECMO or mechanical ventilation at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>For subjects who are in ICU at Day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 negative</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>Time to SARS-CoV-2 negative by reverse transcriptase-polymerase chain reaction (RT-PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative oropharyngeal or nasopharyngeal swab</measure>
    <time_frame>Up to 28 days post baseline</time_frame>
    <description>Proportion of patients with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT PCR on days 5, 10, 14, 21, and 28 after starting treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>Proportion of subjects with serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation due to adverse events</measure>
    <time_frame>Up to 60 days post baseline</time_frame>
    <description>Proportion of subjects who discontinue study drug due to adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Imatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib oral 400 mg daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo oral for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Therapeutic</description>
    <arm_group_label>Imatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients may be included in the study only if they meet all of the following criteria:

          1. Ability to understand and willingness to sign a written informed consent document.
             Informed consent must be obtained prior to participation in the study. For patients
             who are too unwell to provide consent such as patients on invasive ventilator or ECMO,
             Legally Authorized Representative (LAR) can sign the informed consent.

          2. Hospitalized patients ≥ 18 years of age

          3. Positive RT-PCR assay for SARS-CoV-2 in the respiratory tract sample (oropharyngeal,
             nasopharyngeal or BAL) by Center for Disease Control or local laboratory within 7 days
             of randomization.

        Exclusion Criteria

        Patients meeting any of the following criteria are not eligible for the study:

          1. Patients receiving any other investigational agents in a clinical trial. Off-label use
             of agents such as hydroxychloroquine is not an exclusion criterion. Therapies that are
             shown to be effective but may not be licensed can be added as an exception to the
             exclusion criteria in order to allow for the most contemporary standard of care to
             include emergency use authorization treatments as they become available. Antivirals
             such as remdesivir will be permissible given the FDA authorized emergency use.

          2. Pregnant or breastfeeding women.

          3. Patients with significant liver or renal dysfunction function at screen as defined as:

               -  Direct bilirubin &gt; 2.5 mg/dL

               -  AST, ALT, or alkaline phosphatase &gt; 5 x upper limit of normal

               -  eGFR ≤ 30 mL/min or requiring renal replacement therapy

          4. Patients with significant hematologic disorder at screen as defined as:

               -  Absolute neutrophil count (ANC) &lt; 500/μL

               -  Platelet &lt; 20,000/μL

               -  Hemoglobin &lt; 7 g/dL

          5. Uncontrolled undercurrent illness including, but not limited to, symptomatic
             congestive heart failure, unstable angina pectoris, uncontrolled active seizure
             disorder, or psychiatric illness/social situations that per site Principal
             Investigator's judgment would limit compliance with study requirements.

          6. Known allergy to imatinib or its component products.

          7. Any other clinical conditions that in the opinion of the investigator would make the
             subject unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashkan Emadi, MD, PhD</last_name>
    <phone>410-328-2596</phone>
    <email>aemadi@umm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monica Estrada</last_name>
    <email>monica.estrada@umm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashkan Emadi, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021588s053lbl.pdf</url>
    <description>FDA. Imatinib Label. Food and Drug Administration 2018</description>
  </link>
  <link>
    <url>http://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus/en/</url>
    <description>WHO. Coronavirus disease (COVID-2019) R&amp;D Blueprint. World Health Organization 2020</description>
  </link>
  <reference>
    <citation>Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.</citation>
    <PMID>32007143</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020 May 5;133(9):1025-1031. doi: 10.1097/CM9.0000000000000744.</citation>
    <PMID>32044814</PMID>
  </reference>
  <reference>
    <citation>Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.</citation>
    <PMID>32031570</PMID>
  </reference>
  <reference>
    <citation>Al-Bari MA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608-21. doi: 10.1093/jac/dkv018. Epub 2015 Feb 17. Review.</citation>
    <PMID>25693996</PMID>
  </reference>
  <reference>
    <citation>Daniel WA, Bickel MH, Honegger UE. The contribution of lysosomal trapping in the uptake of desipramine and chloroquine by different tissues. Pharmacol Toxicol. 1995 Dec;77(6):402-6.</citation>
    <PMID>8835367</PMID>
  </reference>
  <reference>
    <citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003 Nov;3(11):722-7. Review.</citation>
    <PMID>14592603</PMID>
  </reference>
  <reference>
    <citation>Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013 Feb;23(2):300-2. doi: 10.1038/cr.2012.165. Epub 2012 Dec 4.</citation>
    <PMID>23208422</PMID>
  </reference>
  <reference>
    <citation>Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8.</citation>
    <PMID>15351731</PMID>
  </reference>
  <reference>
    <citation>Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.</citation>
    <PMID>32171740</PMID>
  </reference>
  <reference>
    <citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.</citation>
    <PMID>32020029</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.</citation>
    <PMID>32074550</PMID>
  </reference>
  <reference>
    <citation>Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006 May 4;49(9):2845-9.</citation>
    <PMID>16640347</PMID>
  </reference>
  <reference>
    <citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.</citation>
    <PMID>32150618</PMID>
  </reference>
  <reference>
    <citation>Chapuy B, Panse M, Radunski U, Koch R, Wenzel D, Inagaki N, Haase D, Truemper L, Wulf GG. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug. Haematologica. 2009 Nov;94(11):1528-36. doi: 10.3324/haematol.2009.008631.</citation>
    <PMID>19880777</PMID>
  </reference>
  <reference>
    <citation>Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011 Dec 1;17(23):7337-46. doi: 10.1158/1078-0432.CCR-11-1667. Epub 2011 Oct 6. Erratum in: Clin Cancer Res. 2012 Jan 1;18(1):318.</citation>
    <PMID>21980135</PMID>
  </reference>
  <reference>
    <citation>Gotink KJ, Rovithi M, de Haas RR, Honeywell RJ, Dekker H, Poel D, Azijli K, Peters GJ, Broxterman HJ, Verheul HM. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Cell Oncol (Dordr). 2015 Apr;38(2):119-29. doi: 10.1007/s13402-015-0218-8. Epub 2015 Feb 11.</citation>
    <PMID>25665527</PMID>
  </reference>
  <reference>
    <citation>Colombo F, Trombetta E, Cetrangolo P, Maggioni M, Razini P, De Santis F, Torrente Y, Prati D, Torresani E, Porretti L. Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells. PLoS One. 2014 Dec 10;9(12):e114787. doi: 10.1371/journal.pone.0114787. eCollection 2014.</citation>
    <PMID>25493932</PMID>
  </reference>
  <reference>
    <citation>Ruzickova E, Skoupa N, Dolezel P, Smith DA, Mlejnek P. The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance. Biomolecules. 2019 Oct 31;9(11). pii: E675. doi: 10.3390/biom9110675.</citation>
    <PMID>31683643</PMID>
  </reference>
  <reference>
    <citation>Burger H, den Dekker AT, Segeletz S, Boersma AW, de Bruijn P, Debiec-Rychter M, Taguchi T, Sleijfer S, Sparreboom A, Mathijssen RH, Wiemer EA. Lysosomal Sequestration Determines Intracellular Imatinib Levels. Mol Pharmacol. 2015 Sep;88(3):477-87. doi: 10.1124/mol.114.097451. Epub 2015 Jun 24.</citation>
    <PMID>26108972</PMID>
  </reference>
  <reference>
    <citation>Fu D, Zhou J, Zhu WS, Manley PW, Wang YK, Hood T, Wylie A, Xie XS. Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem. 2014 Jul;6(7):614-22. doi: 10.1038/nchem.1961. Epub 2014 May 25.</citation>
    <PMID>24950332</PMID>
  </reference>
  <reference>
    <citation>Chilakapati SR, Serasanambati M, Vissavajjhala P, Kanala JR, Chilakapati DR. Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib. Exp Lung Res. 2015 May;41(4):173-88. doi: 10.3109/01902148.2014.939312. Epub 2015 Apr 6.</citation>
    <PMID>25844688</PMID>
  </reference>
  <reference>
    <citation>Li M, Abdollahi A, Gröne HJ, Lipson KE, Belka C, Huber PE. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol. 2009 Dec 21;4:66. doi: 10.1186/1748-717X-4-66.</citation>
    <PMID>20025728</PMID>
  </reference>
  <reference>
    <citation>Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H. The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13622-7. Epub 2005 Sep 8.</citation>
    <PMID>16174751</PMID>
  </reference>
  <reference>
    <citation>Rizzo AN, Sammani S, Esquinca AE, Jacobson JR, Garcia JG, Letsiou E, Dudek SM. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am. J. Physiol. Lung Cell Mol. Physiol.. 2015 Dec 1;309(11):L1294-304. doi: 10.1152/ajplung.00031.2015. Epub 2015 Oct 2.</citation>
    <PMID>26432864</PMID>
  </reference>
  <reference>
    <citation>Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7. Review.</citation>
    <PMID>32034323</PMID>
  </reference>
  <reference>
    <citation>Horne GA, Stobo J, Kelly C, Mukhopadhyay A, Latif AL, Dixon-Hughes J, McMahon L, Cony-Makhoul P, Byrne J, Smith G, Koschmieder S, BrÜmmendorf TH, Schafhausen P, Gallipoli P, Thomson F, Cong W, Clark RE, Milojkovic D, Helgason GV, Foroni L, Nicolini FE, Holyoake TL, Copland M. A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. Leukemia. 2020 Jul;34(7):1775-1786. doi: 10.1038/s41375-019-0700-9. Epub 2020 Jan 10.</citation>
    <PMID>31925317</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis. 2020 Apr 27;221(10):1688-1698. doi: 10.1093/infdis/jiz656.</citation>
    <PMID>31822885</PMID>
  </reference>
  <reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </reference>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6. Review.</citation>
    <PMID>26246395</PMID>
  </reference>
  <reference>
    <citation>Cutler DJ, MacIntyre AC, Tett SE. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl. 1988;24:142-57.</citation>
    <PMID>3263755</PMID>
  </reference>
  <reference>
    <citation>Tett SE. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet. 1993 Nov;25(5):392-407. Review.</citation>
    <PMID>7904547</PMID>
  </reference>
  <reference>
    <citation>Carmichael SJ, Charles B, Tett SE. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit. 2003 Dec;25(6):671-81.</citation>
    <PMID>14639053</PMID>
  </reference>
  <reference>
    <citation>Yusuf IH, Foot B, Galloway J, Ardern-Jones MR, Watson SL, Yelf C, Burdon MA, Bishop PN, Lotery AJ. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye (Lond). 2018 Jul;32(7):1168-1173. doi: 10.1038/s41433-018-0136-x. Epub 2018 Jun 11. Review.</citation>
    <PMID>29887605</PMID>
  </reference>
  <reference>
    <citation>Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. Drug Saf. 2018 Oct;41(10):919-931. doi: 10.1007/s40264-018-0689-4.</citation>
    <PMID>29858838</PMID>
  </reference>
  <reference>
    <citation>McHenry AR, Wempe MF, Rice PJ. Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes. Int J Pharm Compd. 2017 May-Jun;21(3):251-254.</citation>
    <PMID>28557788</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Ashkan Emadi, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

